Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)
A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)
Sponsor: Kala Pharmaceuticals, Inc.
This PHASE3 trial investigates Kerato Conjunctivitis Sicca and is currently completed. Kala Pharmaceuticals, Inc. leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
May 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — May 2021 [monthly]
Completed PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Apr 2020 [monthly]
Recruiting PHASE3
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE3
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kala Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .